1-Jahres-Chart
5-Tage-Chart
| Realtime | Geld | Brief | Zeit |
|---|---|---|---|
| 0,394 | 0,474 | 07:00 |
- Alle
- Pressemitteilungen
- Empfehlungen
- Chartanalysen
- Berichte
| Zeit | Aktuelle Nachrichten Sprache:
Alle DE EN | Leser | Medien | ||
|---|---|---|---|---|---|
| 14.11. | Merck KGaA/Abbisko share positive phase 3 results for pimicotinib in rare tumour type | 26 | PMLiVE | ||
| 13.11. | ABBISKO-B (02256): VOLUNTARY ANNOUNCEMENT - ABBISKO THERAPEUTICS PRESENTED RESULTS ON MODEL-INFORMED DOSE SELECTION FOR PIMICOTINIB AT ACOP 2024 | 1 | HKEx | ||
| 12.11. | Abbisko: Pimicotinib Significantly Improved Outcomes for Patients with Tenosynovial Giant Cell Tumor in a Global Phase III Trial | 88 | PR Newswire | - The MANEUVER study met the primary endpoint with an objective response rate (ORR) at week 25 of 54.0% compared with 3.2% for placebo (p- Statistically significant... ► Artikel lesen | |
| 12.11. | ABBISKO-B (02256): INSIDE INFORMATION - POSITIVE TOP-LINE RESULTS FROM PIVOTAL PHASE 3 MANEUVER STUDY OF PIMICOTINIB IN TGCT PATIENTS AND UPDATED RESULTS ... | 1 | HKEx | ||
| ABBISKO CAYMAN Aktie jetzt für 0€ handeln | |||||
| 08.11. | ABBISKO-B (02256): VOLUNTARY ANNOUNCEMENT - ABBISKO THERAPEUTICS TO PRESENT PRELIMINARY PHASE 2 STUDY RESULTS OF PIMICOTINIB FOR THE TREATMENT OF CGVHD ... | 2 | HKEx | ||
| 23.10. | ABBISKO-B (02256): VOLUNTARY ANNOUNCEMENT - ABBISKO THERAPEUTICS PRESENTED PRECLINICAL RESEARCH RESULTS OF ITS PRMT5*MTA AND ORAL KRASG12D PROGRAMS AT ... | - | HKEx | ||
| 30.09. | ABBISKO-B (02256): NEXT DAY DISCLOSURE RETURN - CHANGES IN ISSUED SHARE CAPITAL | - | HKEx | ||
| 30.09. | ABBISKO-B (02256): VOLUNTARY ANNOUNCEMENT - ON-MARKET SHARE REPURCHASE AND REPURCHASED SHARES CANCELLATION | 1 | HKEx | ||
| 24.09. | ABBISKO-B (02256): VOLUNTARY ANNOUNCEMENT - ABK3376 OBTAINED IND APPROVAL FROM NMPA | - | HKEx | ||
| 19.09. | ABBISKO-B (02256): 2024 INTERIM REPORT | 1 | HKEx | ||
| 30.08. | ABBISKO-B (02256): NEXT DAY DISCLOSURE RETURNS | - | HKEx | ||
| 22.08. | ABBISKO-B (02256): NEXT DAY DISCLOSURE RETURNS | - | HKEx | ||
| 14.08. | ABBISKO-B (02256): NEXT DAY DISCLOSURE RETURNS | - | HKEx | ||
| 12.08. | ABBISKO-B (02256): INTERIM RESULTS ANNOUNCEMENT FOR THE SIX MONTHS ENDED JUNE 30, 2024 | - | HKEx | ||
| 26.07. | ABBISKO-B (02256): DATE OF BOARD MEETING | 1 | HKEx | ||
| 10.07. | ABBISKO-B (02256): POSITIVE PROFIT ALERT | - | HKEx | ||
| 04.07. | ABBISKO-B (02256): VOLUNTARY ANNOUNCEMENT - ON-MARKET SHARE REPURCHASE | 1 | HKEx | ||
| 03.07. | ABBISKO-B (02256): NEXT DAY DISCLOSURE RETURN - CHANGES IN ISSUED SHARE CAPITAL | 1 | HKEx | ||
| 28.06. | ABBISKO-B (02256): NEXT DAY DISCLOSURE RETURNS | - | HKEx | ||
| 28.06. | ABBISKO-B (02256): VOLUNTARY ANNOUNCEMENT - 2024 ESMO-GI | ABBISKO THERAPEUTICS PRESENTS NEW PHASE II CLINICAL DATA OF IRPAGRATINIB IN COMBINATION WITH ... | 1 | HKEx |
Seite:
1 2 Weiter >>
33 Nachrichten in den letzten 12 Monaten
| Unternehmen / Aktien | Aktienkurs | % | Top-Nachrichten | ||
|---|---|---|---|---|---|
| ADMA BIOLOGICS | 21,370 | 0,00 % | Adma Biologics Aktie: Erholung nach starkem Kursrückgang | ||
| RECURSION PHARMACEUTICALS | 6,040 | 0,00 % | Recursion Pharmaceuticals, Inc.: Recursion and Exscientia, two leaders in the AI drug discovery space, have officially combined to advance the industrialization of drug discovery | Recursion unveils post-combination technology-enabled portfolio with more than 10 clinical and preclinical programs, 10 advanced discovery programs, and more than 10 partnered programsPlatform will... ► Artikel lesen | |
| EVOTEC | 9,935 | +0,30 % | Evotec Aktie: Optimistische Marktprognosen! | ||
| QIAGEN | 39,860 | +2,63 % | Neue 6,00% Aktienanleihe mit Barriere auf QIAGEN in Zeichnung | München (www.anleihencheck.de) - Die Experten vom Zertifikate-Team der Bank Vontobel Europe AG bieten eine neue Aktienanleihe (ISIN DE000VC7RDU1/ WKN VC7RDU) mit Barriere auf die Aktie von QIAGEN (ISIN... ► Artikel lesen | |
| QUANTUM-SI | 1,400 | 0,00 % | Quantum-Si Inc - 8-K, Current Report | ||
| 89BIO | 7,980 | 0,00 % | 89bio, Inc.: 89bio Presents New Analyses Evaluating Pegozafermin and Potential Benefit of Non-Invasive Tests from the ENLIVEN Phase 2b Trial in MASH Patients at AASLD The Liver Meeting 2024 | SAN FRANCISCO, Nov. 15, 2024 (GLOBE NEWSWIRE) -- 89bio, Inc. (Nasdaq: ETNB), a clinical-stage biopharmaceutical company focused on the development and commercialization of innovative therapies for... ► Artikel lesen | |
| LONGBOARD PHARMACEUTICALS | 59,76 | 0,00 % | Longboard Pharmaceuticals Reports Third Quarter 2024 Financial Results and Provides Corporate Updates | LA JOLLA, Calif.--(BUSINESS WIRE)--Longboard Pharmaceuticals, Inc. (Nasdaq: LBPH), a clinical-stage biopharmaceutical company focused on developing novel, transformative medicines for neurological... ► Artikel lesen | |
| RELAY THERAPEUTICS | 4,660 | 0,00 % | Aktie von Relay Therapeutics erreicht 52-Wochen-Tief bei 5,59 US-Dollar | ||
| STRUCTURE THERAPEUTICS | 32,710 | 0,00 % | Structure Therapeutics reports Q3 results | ||
| SPRINGWORKS THERAPEUTICS | 37,440 | 0,00 % | SpringWorks started at outperform by Evercore ahead of FDA decision | ||
| 4D MOLECULAR THERAPEUTICS | 8,410 | 0,00 % | Analyst Expectations For 4D Molecular Therapeutics' Future | ||
| DYNE THERAPEUTICS | 30,000 | 0,00 % | Wissenschaftliche Leiterin von Dyne Therapeutics verkauft Aktien im Wert von 80.539 US-Dollar | ||
| CULLINAN THERAPEUTICS | 12,580 | 0,00 % | Cullinan Therapeutics, Inc.: Cullinan Therapeutics Announces Preclinical Data for CLN-978, a CD19-directed T Cell Engager, to be Presented at ACR Convergence 2024 | Cullinan will present new in vitro preclinical data that provide further strong rationale for broad clinical development of CLN-978 in autoimmune diseases Cullinan will share details of global Phase... ► Artikel lesen | |
| VIR BIOTECHNOLOGY | 6,740 | 0,00 % | Needham & Company LLC Reaffirms Buy Rating for Vir Biotechnology (NASDAQ:VIR) | ||
| VERVE THERAPEUTICS | 4,550 | 0,00 % | Verve Therapeutics Announces Inducement Grants under Nasdaq Listing Rule 5635(c)(4) | BOSTON, Nov. 01, 2024 (GLOBE NEWSWIRE) -- Verve Therapeutics, a clinical-stage company developing a new class of genetic medicines for cardiovascular disease, today announced that on October 31, 2024... ► Artikel lesen |
ABBISKO CAYMAN LTD gehört der Branche Biotechnologie an. Mit einer aktuellen Kursveränderung von +0,035 (+7,00 %) liegt der Kurs bei 0,535 Euro.
VerkaufenHaltenKaufen
■ Verkaufen
■ Halten
■ Kaufen
Sie erhalten auf FinanzNachrichten.de kostenlose Realtime-Aktienkurse von und .
Weitere Kennzahlen, Fundamentaldaten und Unternehmensinformationen zu ABBISKO CAYMAN LTD finden Sie auf Wallstreet Online.
